Redemplo

(Plozasiran)

Phase 3RNA therapy

Arrowhead Pharmaceuticals

Redemplo is one of 17 small molecule programs targeting Familial Chylomicronemia Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Familial Chylomicronemia SyndromeCompleted

HypertriglyceridemiaActive, not recruiting

Familial Chylomicronemia SyndromePhase 3

Completed

HypertriglyceridemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Hypertriglyceridemia

#DrugCompanyPhaseTrials

Crestor

Selzentry

Cipro

Lopid

Topamax

Zocor

Tryngolza (autoinjector)

Ionis Pharmaceuticals

Phase 3

3 8

Redemplo

Arrowhead Pharmaceuticals

Phase 3

3 9

SHR-1918

BBeijing Suncadia Pharmaceuticals Co., Ltd

Phase 3

1 10

Avandia

Jazz Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Active, not recruiting

Hypertriglyceridemia

NCT06822790

Q2 2029

Phase 3Recruiting

Severe Hypertriglyceridemia

NCT06880770

Clinical

Trials by Indication[1]

Hypertriglyceridemia3 trials

Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS

Available· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals··NCT06796426

A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (SHASTA-10 Study)

Active, not recruiting· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 3·NCT06822790·710 enrolled

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia

Completed· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 3·NCT06347133·1,456 enrolled

Severe Hypertriglyceridemia3 trials

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in Adults With Severe Hypertriglyceridemia

Completed· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 3·NCT06347016·311 enrolled

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia

Completed· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 3·NCT06347003·446 enrolled

Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)

Recruiting· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 3·NCT06880770·288 enrolled

Familial Chylomicronemia Syndrome2 trials

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Active, not recruiting· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 3·NCT05089084·75 enrolled

A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome

Completed·VVisirna Therapeutics HK Limited·Phase 3·NCT05902598·37 enrolled

Regulatory

FDA Approval Timeline[4]

Nov 18, 2025

REDEMPLO

NDA NDA219947

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Plozasiran. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Plozasiran compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Plozasiran. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA219947). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Redemplo. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Arrowhead Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 3[1]
Company: Arrowhead Pharmaceuticals

Patent Landscape[5]

Patent Cliff

Mar 7, 2037

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10294474Mar 7, 2037

11174481Mar 7, 2037

12365899Sep 10, 2038

11214801Sep 10, 2038

10597657Sep 10, 2038

Redemplo

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q2 2029

Trials by Indication[1]

Hypertriglyceridemia3 trials

Severe Hypertriglyceridemia3 trials

Familial Chylomicronemia Syndrome2 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News